Mercaptopurine BNM New Zealand - engelsk - Medsafe (Medicines Safety Authority)

mercaptopurine bnm

boucher & muir (new zealand) limited t/a bnm group - mercaptopurine 50mg - tablet - 50 mg - active: mercaptopurine 50mg excipient: lactose magnesium stearate maize starch pregelatinised maize starch stearic acid - mercaptopurine is indicated for the treatment of acute leukaemia in adults, adolescents and children. it may be utilised in remission induction and is particularly indicated for maintenance therapy in: · acute lymphoblastic leukaemia; · acute myelogenous leukaemia.